Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Transgene, Jennerex Cancer Therapy Improves Survival in Study

Nov. 7 (Bloomberg) -- Transgene SA and Jennerex Biotherapeutics said the high doses of their JX594/TG6006 therapy improved overall survival in advanced liver cancer patients, citing a mid-stage study of 30 patients.

Patients receiving the treatment at the higher dose lived a medial of 13.8 months, compared with 6.7 months for those who received the lower dose, Strasbourg, France-based Transgene and San Francisco-based Jennerex said in an e-mailed statement today. The findings are being presented at the American Association for the Study of Liver Diseases meeting in San Francisco today.

JX594/TG6006 is a virus that is engineered to target and destroy cancerous cells, according to the companies.

To contact the reporter on this story: Kristen Hallam in London at khallam@bloomberg.net

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.